News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi
Jaguar Health, Inc. provides updates on rare disease program for crofelemer, focusing on intestinal failure treatment milestones, Orphan Drug Designation, and global development efforts -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts
Jaguar Health announces virtual presentation by CEO Lisa Conte at Lytham Partners Healthcare Investor Summit. Company focuses on developing plant-based medicines for gastrointestinal distress -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
Jaguar Health, Inc. enters U.S. licensing agreement with Future Pak, LLC for exclusive marketing rights of Mytesi® and Canalevia®-CA1, securing $18M upfront payment and potential $20M in milestone payments -
